Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06928662CT.gov Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | — | Recruiting | — | — | — |
NCT06778187CT.gov Oral-ATO for TP53-mutated Myeloid Malignancies | — | Recruiting | — | — | — |
NCT05883956CT.gov A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT05636514CT.gov Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | — | Recruiting | — | — | — |
NCT05456269CT.gov A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | — | Withdrawn | — | — | — |
NCT05184842CT.gov Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | — | Recruiting | — | — | — |
NCT04980404CT.gov Inqovi Maintenance Therapy in Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT04891757CT.gov FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT04146038CT.gov Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | — | Completed | — | — | — |
NCT03813186CT.gov Effect of Food on Blood Levels of ASTX727 | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT03613532CT.gov Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | — | Active Not Recruiting | — | — | — |
NCT03358719CT.gov DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03306264CT.gov Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | — | Completed | — | — | — |
NCT03404193CT.gov Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT03066648CT.gov Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT03146871CT.gov Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | — | Terminated | — | — | — |
NCT02129101CT.gov Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | — | Completed | — | — | — |
NCT01834248CT.gov DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02190695CT.gov Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | — | Completed | — | — | — |
NCT00357708CT.gov Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | Fred Hutchinson Cancer Center | P3 | BB · 64 |
| Pevonedistat | Takeda | P3 | BB |
| Venetoclax | Servier Bio-Innovation LLC | P2/3 | BB |
| Astx727 | Taiho Oncology, Inc. | P3 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Azacitidine | The University of Hong Kong | P3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BB |
+42 more in the Chronic Myelomonocytic Leukemia cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Chronic Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-chronic-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →